Quick Answer
Esperion Therapeutics, Inc. reported Operating Income Loss of $60.27 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +10.8% in Operating Income Loss from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Esperion Therapeutics, Inc.'s Operating Income Loss has grown by 693.0%.
- Historical annual values: Fiscal year 2025: $60.27 million | Fiscal year 2024: $54.40 million | Fiscal year 2023: -$155.56 million | Fiscal year 2022: -$179.50 million | Fiscal year 2021: -$226.73 million | Fiscal year 2020: -$121.40 million | Fiscal year 2019: -$93.10 million | Fiscal year 2018: -$204.59 million | Fiscal year 2017: -$168.98 million | Fiscal year 2016: -$76.15 million | Fiscal year 2015: -$50.04 million | Fiscal year 2014: -$36.22 million | Fiscal year 2013: -$22.76 million | Fiscal year 2012: -$10.20 million | Fiscal year 2011: -$10.16 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: